This study wants to use eye-tracking technology to study attentional biases, reward sensitivity, and cognitive control in adult patients with bipolar disorder with or without anxiety and/or substance use disorder comorbidity.
Official registry: https://clinicaltrials.gov/study/NCT03829787 · University Hospitals Cleveland Medical Center · enrollment listed as 100
This is an observational study. You are not assigned a new experimental drug. Researchers measure what already happens in your care or in daily life.
Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.
This listing is observational (StudyType). The registry does not assign a new experimental drug as the study intervention.
They plan to enroll about 100 people at Cleveland. Taking part typically means using or being fitted with a device plus check-ins.
Attentional Biases, Reward Sensitivity, and Cognitive Control in Adults With Bipolar Disorder and Different Psychiatric Comorbidities: An Eye-Tracking Study
Interventions: Eye tracking
Primary outcome (registry wording): Measure the differences in attentional bias among the 5 groups by assessing how long it takes a subject to locate and fixate on each face on the screen
Nicole Jones
Published on ClinicalTrials.gov. Contact them as a possible participant. They decide eligibility.
Background: More than 12,000 people have taken part in research at the Experimental Therapeutics \& Pathophysiology Branch at the National Institute of Mental Health Intramural Program. This has led to advances in the treatment of depression, bipolar disorder, and suicide risk.
NCT04877977 · Official ClinicalTrials.gov record · National Institute of Mental Health (NIMH)
Background: Mood disorders, such as bipolar disorder, can have serious effects on a person s life. People with bipolar disorder are more likely to have heart disease and abuse substances.
NCT05669703 · Official ClinicalTrials.gov record · National Institute of Mental Health (NIMH)
This is a multicenter, global, 26-week, open-label study to assess the whether it is safe and how hard side effects are to live with of lumateperone in pediatric patients with schizophrenia, bipolar disorder or autism spectrum disorder.
NCT06229210 · Official ClinicalTrials.gov record · Intra-Cellular Therapies, Inc.
The sponsor posted status “Recruiting” on ClinicalTrials.gov at last ingest. Sites can pause independently. Confirm with the official record and the listed contact.
Not a traditional drug phase. Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.
No. The inclusion and exclusion lists on this page are readable extracts of the public eligibility block. Only the study team can screen you.
How to read a ClinicalTrials.gov record · Questions to ask the coordinator · Glossary